Differential proteostasis imbalance and the molecular basis of distinct synucleinopathies and tauopathies

Abstract

This short review discusses the structural and molecular events at the origin of diverse debilitating neurodegenerative diseases. The pathological consequences owing to the primary, secondary, tertiary and quaternary structural diversity of alpha-synuclein and tau proteins and the aggregates they form are presented. The crosstalk between alpha-synuclein and tau proteins aggregates structural heterogeneity and cellular homeostasis, and more precisely the proteostasis network is next considered. Overall, the proteostasis network appears as the master regulator of distinct synucleinopathies and tauopathies progression depending on its capacity to clear and/or disassemble to completion structurally diverse alpha-synuclein or tau fibrillar aggregates or not. This article is part of the Theo Murphy meeting issue 'ProteostaSys: a systems view of proteostasis'.

Molecular mechanism of LRRC15 protein regulating Treg/Th17 cell imbalance through the PI3K/Akt/mTORC1 signaling pathway in Taenia solium cysticercus infection
Shunfu Yu, Xiaoqing Sun, Qianqian Mu +2
Scientific Reports1 Jun 2026Peer-reviewedCC BYFull textGeneral medicineDOAJ
The characteristics of perivascular proinflammation in 4-repeat tauopathies.
Mu-Hui Fu, Gokhan Uruk, Rodolfo G Gatto +3
Brain pathology (Zurich, Switzerland)28 Oct 2026Peer-reviewedCC BYFull textNeurologyEurope PMCPMC
Differential Modulation of WNT/β‐Catenin Pathway‐Associated Molecular Responses by Palmitate and Oleate in Lipid‐Loaded HepG2 Cells
Moayed Al‐Haeri, Yaser Mohammadi, Roghiyeh Pashaei‐Asl +1
Cancer reports (Hoboken, N.J.)1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Human DOPA Decarboxylase in Monoamine Metabolism, Pharmacology, and Synucleinopathies.
Davide Chiasserini, Giovanni Bellomo, Pier Luigi Orvietani +1
ACS bio & med chem Au26 Aug 2026Peer-reviewedCC BYFull textNeurologyEurope PMC
Regulatory endorsement for the application of α-synuclein seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies
Diane Stephenson, Luis Concha-Marambio, Tom Lanz +8
Journal of Parkinson's Disease24 Jul 2026Peer-reviewedCC BY-NC 4.0Full text1 citedNeurologyPMC

Cite

BibTeX RIS

BibTeX

@article{redeker2026differential,
  title = {{Differential proteostasis imbalance and the molecular basis of distinct synucleinopathies and tauopathies}},
  author = {Virginie Redeker and Ronald Melki},
  journal = {Philosophical Transactions of the Royal Society B: Biological Sciences},
  year = {2026},
  month = oct,
  doi = {10.1098/rstb.2025.0272},
  url = {https://hal.science/hal-05854559v1},
  note = {CC BY 4.0},
}

RIS

TY  - JOUR
TI  - Differential proteostasis imbalance and the molecular basis of distinct synucleinopathies and tauopathies
AU  - Virginie Redeker
AU  - Ronald Melki
PY  - 2026
DA  - 2026/10/01
JO  - Philosophical Transactions of the Royal Society B: Biological Sciences
DO  - 10.1098/rstb.2025.0272
UR  - https://hal.science/hal-05854559v1
AB  - This short review discusses the structural and molecular events at the origin of diverse debilitating neurodegenerative diseases. The pathological consequences owing to the primary, secondary, tertiary and quaternary structural diversity of alpha-synuclein and tau proteins and the aggregates they form are presented. The crosstalk between alpha-synuclein and tau proteins aggregates structural heterogeneity and cellular homeostasis, and more precisely the proteostasis network is next considered. Overall, the proteostasis network appears as the master regulator of distinct synucleinopathies and tauopathies progression depending on its capacity to clear and/or disassemble to completion structurally diverse alpha-synuclein or tau fibrillar aggregates or not. This article is part of the Theo Murphy meeting issue 'ProteostaSys: a systems view of proteostasis'.
SN  - 0962-8436
SN  - 1471-2970
ER  -

Abstract

Related

Cite